Sanofi-aventis Third Quarter 2005: Adjusted EPS(1) up 27.4%, Net Sales up 11.0% on a Comparable Basis(1) First 9 Months of 2005: Adjusted EPS(1) up 26.6%,

Net Sales up 11.0% on a Comparable Basis(1)



    PARIS, Nov. 8 /PRNewswire-FirstCall/ -- The consolidated income statement
 for the first 9 months of 2005 is shown in Appendix 4. Consolidated net income
 for the first 9 months of 2005 was euro 1,802 million. This figure takes
 account of the effects of the application of purchase accounting to the
 Aventis acquisition, including an impairment loss of euro 339 million net of
 deferred tax arising from the launch of generics of Allegra in the United
 States in September 2005 and post-tax restructuring costs of euro 465 million.
     In order to give a better representation of our underlying economic
 performance, we have decided to publish and explain adjusted(1) consolidated
 income statements for the first 9 months of 2005 and the third quarter of
 2005, and to compare them with adjusted proforma(1) income statements for the
 first 9 months of 2004 and the third quarter of 2004 respectively. Adjusted
 net income for the first 9 months of 2005 was euro 4,891 million, compared
 with euro 3,830 million for the first 9 months of 2004.
 
     THIRD QUARTER
     -- Net sales: euro 7,200 million, up 11.6% (11.0% on a comparable basis).
     -- 20.2% growth in "Adjusted operating income - current".
     -- 28.7% rise in adjusted net income to euro 1,923 million.
     -- 27.4% increase in adjusted EPS to euro 1.44 (vs. euro 1.13 for the
        third quarter of 2004).
 
     FIRST 9 MONTHS
     -- Net sales: euro 20,304 million, up 8.9% (11.0% on a comparable basis).
     -- 23.8% growth in "Adjusted operating income - current".
     -- 27.7% rise in adjusted net income to euro 4,891 million.
     -- 26.6% increase in adjusted EPS to euro 3.66 (vs. euro 2.89 for the
        first 9 months of 2004).
 
     CONFIRMATION OF 2005 GUIDANCE
     Barring major adverse events, despite impact of Allegra(R) in Q4 2005, the
 Group confirms its guidance of adjusted EPS growth in 2005 of at least 20%(2).
 
     Net sales for third quarter of 2005 and first 9 months of 2005
     Unless otherwise indicated, growth figures in this press release are on a
 comparable basis and calculated on 2004 pro forma figures (see explanatory
 notes).
     In the third quarter of 2005, sanofi-aventis generated net sales of euro
 7,200 million, up 11.0%. Exchange rate movements had a favorable effect of 1.3
 points, and changes in Group structure a negative effect of 0.7 of a point.
 After allowing for these impacts, reported-basis growth was 11.6%.
     Net sales for the 9 months to end September 2005 totaled euro 20,304
 million, up 11.0%. Exchange rate movements had a negative effect of 1.2
 points, and changes in Group structure a negative effect of 0.9 of a point.
 After allowing for these impacts, reported-basis growth was 8.9%.
 
     Net sales by business segment
     Net sales reported by sanofi-aventis comprise net sales generated by the
 pharmaceuticals business and net sales generated by the human vaccines
 business.
 
     Pharmaceuticals
     Third-quarter net sales for the pharmaceuticals business were up 9.4% at
 euro 6,483 million. Net sales of the top 15 products rose by 15.7% to euro
 4,283 million, representing 66.1% of pharmaceuticals net sales, compared with
 62.5% for the third quarter of 2004.
     In the 9 months to end September 2005, net sales for the pharmaceuticals
 business were up 10.5% at euro 18,885 million. Net sales of the top 15
 products rose by 16.7% to euro 12,076 million, representing 63.9% of
 pharmaceuticals net sales, compared with 60.5% in the 9 months to end
 September 2004.
 
     Millions of euros       2005 Q3    Change on a     2005    Change on a
                             net sales  comparable     9-month   comparable
                                          basis       net sales     basis
     Lovenox(R)                 551       +13.8%        1,571       +15.7%
     Plavix(R)                  534       +22.8%        1,508       +21.4%
     Eloxatin(R)                422       +28.3%        1,141       +35.2%
     Taxotere(R)                420       +13.8%        1,184       +11.9%
     Stilnox(R)/Ambien(R)       419        +5.5%        1,089        +7.6%
     Allegra(R)                 367        -0.8%        1,185        +8.3%
     Lantus(R)                  325       +44.4%          869       +48.5%
     Tritace(R)                 260        +7.0%          724        +1.8%
     Copaxone(R)                240       +23.7%          646       +23.8%
     Aprovel(R)                 225       +14.8%          661       +14.2%
     Amaryl(R)                  195       +19.6%          542       +12.2%
     Actonel(R)                  99       +20.7%          275       +25.6%
     Depakine(R)                 81        +5.2%          238        +5.3%
     Xatral(R)                   80       +15.9%          237       +16.2%
     Nasacort(R)                 65        -7.1%          206        -1.0%
     Total                    4,283       +15.7%       12,076       +16.7%
 
     Third-quarter net sales of other pharmaceutical products were down 1.1% at
 euro 2,200 million. Excluding DDAVP, which faced competition from generics in
 the United States during the quarter, net sales of other pharmaceutical
 products were stable.
     Net sales of other pharmaceutical products for the 9 months to end
 September were up 0.8% at euro 6,809 million.
 
     Human Vaccines
     Third-quarter consolidated net sales for the Human Vaccines business were
 euro 717 million, a rise of 27.8%.
     In the 9 months to end September, consolidated net sales for this business
 reached euro 1,419 million, up 18.5%.
     The successful launch of Menactra(R) in the United States in March 2005
 added euro 77 million to third-quarter net sales and euro 147 million to net
 sales for the first 9 months of the year.
     The fine performance by Adult Booster vaccines benefited from two US
 launches: Decavac(R) in January 2005 (euro 152 million to end September), and
 Adacel(TM) (tetanus-diphtheria-whooping cough-Tdap) in July 2005.
     The influenza vaccination season began as usual in September, and will
 continue through the final quarter.
 
     Net sales
     Millions of euros    2005 Q3     Change on a   2005        Change on a
                          net sales   comparable    9-month     comparable
                                      basis         net sales   basis
     Polio/Whooping Cough/
      Hib Vaccines           151         +14.2%        409         -0.5%
     Adult Booster Vaccines   90         +91.1%        211        +48.2%
     Influenza Vaccines      274          +8.7%        338        +12.4%
     Travel Vaccines          48          +5.2%        129         -3.3%
     Meningitis/
      Pneumonia Vaccines     110        +150.0%        208       +128.6%
     Other Vaccines           44         +12.8%        124         +4.2%
     Total                   717         +27.8%      1,419        +18.5%
 
     Sanofi Pasteur MSD, the joint venture with Merck & Co in Europe, generated
 third-quarter net sales of euro 246 million (up 8.8% on a reported basis). For
 the 9 months to end September, the joint venture posted sales of euro 527
 million (up 9.7% on a reported basis). These sales are not consolidated by
 sanofi-aventis.
 
     Net sales by geographical region
 
     Millions of euros      2005 Q3     Change on a   2005        Change on a
                            net sales   comparable    9-month     comparable
                                          basis       net sales     basis
     Europe                   3,010       +10.1%        9,085        +9.6%
     United States            2,725       +12.9%        7,129       +14.9%
     Other countries          1,465        +9.2%        4,090        +7.7%
     Total                    7,200       +11.0%       20,304       +11.0%
 
     In Europe, third-quarter sales growth was propelled by a strong showing
 from the entire portfolio, and in particular from Lantus(R) (up 44.5%),
 Eloxatin(R) (up 27.7%), Taxotere(R) (up 26.8%), Plavix(R) (up 20.6%) and
 Lovenox(R) (up 12.4%).
     In the United States, despite competition from generics of Allegra(R) in
 September, sales rose by 12.9% in the third quarter, driven by Lantus(R) (up
 38.8%), Eloxatin(R) (up 25.4%) and Lovenox(R) (up 13.4%).
     In other countries, sales growth accelerated, reaching 9.2% in the third
 quarter.
 
     Developed sales
     Developed sales give an indication of the overall presence of sanofi-
 aventis products in the market. Third-quarter developed sales reached euro
 8,110 million, up 10.4%. In the 9 months to end September, developed sales
 amounted to euro 22,732 million, up 11.2%.
 
     Developed sales of Plavix(R)/Iscover(R):
 
     Millions of euros   2005 Q3   Change on a        2005      Change on a
                                  comparable basis   9 months  comparable basis
     Europe                408       +21.8%           1,165           +21.7%
     United States         685        +7.4%           1,832           +15.8%
     Other countries       149       +22.1%             411           +22.3%
     Total               1,242       +13.4%           3,408           +18.5%
 
     In the United States, total prescriptions (TRx) of Plavix(R) rose by
 13.6%(3) to end September.
     In Europe, Plavix(R) again achieved robust growth in the third quarter,
 especially in France (up 22.4%).
 
     Developed sales of Aprovel(R)/Avapro(R)/Karvea(R):
 
     Millions of euros   2005 Q3   Change on a        2005      Change on a
                                  comparable basis   9 months  comparable basis
     Europe                199       +11.2%             586       +11.8%
     United States         120        -1.6%             319        -0.6%
     Other countries        86       +16.2%             226       +14.7%
     Total                 405        +8.0%           1,131        +8.5%
 
     In the United States, total prescriptions of Avapro(R) (TRx) rose by
 13.1%(3) to end September compared with market growth (ARB) of 10.6%(3). At
 end September, the product had market share of 15.0%(4).
 
 
     Comments by therapeutic class
 
     Cardiovascular/Thrombosis
 
     Lovenox(R) /Clexane(R)
     2005 third-quarter net sales of Lovenox(R) were euro 551 million, up
 13.8%, with growth of 13.4% (to euro 334 million) in the United States and
 12.4% (to euro 159 million) in Europe. In the United States, growth was driven
 largely by the use of Lovenox(R) in medical prophylaxis.
     In the 9 months to end September, net sales of Lovenox(R) rose by 16.8%
 (to euro 934 million) in the United States and by 13.3% (to euro 484 million)
 in Europe.
 
     Plavix(R)
     Third-quarter consolidated net sales of Plavix(R) came to euro 534
 million, up 22.8%. In the 9 months to end September, net sales of the product
 rose by 21.4% to euro 1,508 million.
 
     Delix(R)/Tritace(R)
     Third-quarter net sales of Delix(R)/Tritace(R) came to euro 260 million,
 up 7.0%, thanks to a return to growth in Germany and good performances in
 France and Canada.
     In the 9 months to end September, net sales of Delix(R)/Tritace(R) grew by
 1.8% to euro 724 million.
 
     Aprovel(R)
     Third-quarter consolidated net sales of Aprovel(R) came to euro 225
 million, up 14.8%.
     In the 9 months to end September, consolidated net sales of Aprovel(R)
 rose by 14.2% to euro 661 million.
 
 
     Oncology
 
     Taxotere(R)
     Third-quarter consolidated net sales of Taxotere(R) were euro 420 million,
 up 13.8%. In Europe, growth accelerated in the quarter to 26.8% (euro 164
 million), thanks largely to increased sales force effectiveness and clearer
 differentiation between Taxotere(R) and Taxol(R).
     In the United States, Taxotere(R) is gaining market share with new
 patients in early stage breast cancer as an adjuvant treatment (26%(5)) and in
 the treatment of hormone-resistant prostate cancer (82%(5)), but is still
 being adversely affected by the introduction of Taxol(R) generics. Third-
 quarter sales in the United States came to euro 180 million, up 5.9%.
     In the 9 months to end September, net sales of Taxotere(R) were euro 1,184
 million, up 11.9%. The product achieved growth of 19.0% in Europe (to euro 464
 million) and 8.1% in the United States (to euro 512 million).
 
     Eloxatin(R)
     Third-quarter net sales of Eloxatin(R) were euro 422 million, up 28.3%.
 Net sales of the product rose by 25.4% in the United States (to euro 245
 million) and by 27.7% in Europe (to euro 141 million). Eloxatin(R) is gaining
 market share as an adjuvant treatment for colorectal cancer in Europe and in
 the United States, where the product has 59.3%(5) market share in stage III
 patients.
     In the 9 months to end September, net sales of Eloxatin(R) advanced by
 35.1% in the United States (to euro 651 million) and by 34.4% in Europe (to
 euro 404 million). A new formulation (solution) was launched at the start of
 June in the United States and France, and already represents around 80% of
 Eloxatin(R) use.
 
 
     Central Nervous System
 
     Ambien(R)
     Third-quarter net sales of Ambien(R) amounted to euro 371 million in the
 United States, up 4.8%. Prescription growth to end September was 5.9%3 in the
 United States.
     Ambien CR, approved in the United States on September 6, 2005, has been
 available in pharmacies since beginning of October. The product is being
 marketed by a sales force of around 3,500 medical professionals.
     In the 9 months to end September, net sales of Ambien(R) in the United
 States rose 8.8% to euro 948 million. In Japan, sales of Myslee(R) (not
 consolidated by sanofi-aventis) were up 19.4% at euro 76 million.
 
     Copaxone(R)
     Third-quarter net sales of Copaxone(R) came to euro 240 million, up 23.7%.
 Net sales rose by 26.6% in the United States (to euro 168 million), and by
 20.0% in Europe (to euro 59 million).
     In the 9 months to end September, net sales of Copaxone(R) advanced by
 24.8% (to euro 440 million) in the United States and by 23.2% in Europe (to
 euro 170 million).
 
     Depakine(R)
     Third-quarter net sales of Depakine(R) were euro 81 million, up 5.2%. In
 the 9 months to end September, net sales of Depakine(R) increased by 5.3% to
 euro 238 million.
 
 
     Diabetes
 
     Lantus(R)
     Third-quarter net sales of Lantus(R) were euro 325 million, up 44.4%. The
 product reported net sales growth of 38.8% in the United States (to euro 191
 million) and 44.5% in Europe (to euro 110 million). In the United States,
 Lantus(R), the best-selling insulin product on the market and the only insulin
 analog to provide 24-hour coverage, continues to gain market share, and had
 28.1%4 of the market at end September 2005.
     In the 9 months to end September, net sales of Lantus(R) advanced by 45.4%
 in the United States to euro 511 million. In Europe, the product posted sales
 growth of 45.7% to euro 301 million.
 
     Amaryl(R)
     Third-quarter net sales of Amaryl(R) were euro 195 million, up 19.6%. Net
 sales rose by 33.6% in the United States (to euro 63 million), and by 10.0% in
 Europe (to euro 68 million).
     In the 9 months to end September, net sales of Amaryl(R) advanced by 18.9%
 in the United States (to euro 172 million). In Europe, the product achieved
 growth of 11.1%, to euro 195 million.
     In early October, Prasco Laboratories launched an authorized generic of
 Amaryl(R) in the United States.
 
     Internal Medicine
 
     Allegra(R)
     Third-quarter net sales of Allegra(R) fell by 0.8% to euro 367 million,
 including euro 305 million in the United States (down 0.9%). Allegra(R) has
 been facing competition from generics in the United States since September. On
 September 14, 2005, Prasco Laboratories launched an authorized generic version
 of Allegra(R).
     In the 9 months to end September, net sales of Allegra(R) rose by 8.3% to
 euro 1,185 million. Net sales in the United States were up 5.6% at euro 914
 million.
 
     Actonel(R)
     Third-quarter worldwide sales of Actonel(R), including the alliance with
 Procter & Gamble, amounted to euro 387 million. Sales consolidated by sanofi-
 aventis were up 20.7% at euro 99 million. Consolidated Japanese sales for the
 third quarter rose by 10.6% to euro 13 million.
     In the 9 months to end September, worldwide sales of Actonel(R), including
 the alliance with Procter & Gamble, totaled euro 1,009 million. Sales
 consolidated by sanofi-aventis over the period were euro 275 million, an
 increase of 25.6%.
 
     Ketek(R)
     Third-quarter net sales of Ketek(R) were euro 38 million, 7.3% lower than
 in the third quarter of 2004, when the product was launched in the United
 States.
     In the 9 months to end September, net sales of Ketek(R) increased by 35.9%
 to euro 159 million.
 
     Xatral(R)
     Third-quarter net sales of Xatral(R) came to euro 80 million, up 15.9%.
     In the 9 months to end September, net sales of Xatral(R) advanced by 16.2%
 to euro 237 million.
 
 
     Adjusted consolidated income statement (unaudited)
     The adjusted consolidated income statement (unaudited) is presented in
 Appendix 3.
     Refer to Appendix 1 for a definition of "Proforma income statement" and
 "Adjusted net income", and to Appendix 4 for reconciliations of the
 consolidated income statement to the adjusted consolidated income statement.
 
     Third quarter of 2005 (vs. 2004 third-quarter adjusted pro forma)
     Net sales generated by sanofi-aventis in the third quarter of 2005 came to
 euro 7,200 million, an increase of 11.0% on a comparable basis. Exchange rate
 movements had a favorable effect of 1.3 points, and changes in Group structure
 a negative effect of 0.7 of a point. After allowing for these impacts,
 reported-basis growth was 11.6%.
     Gross profit was euro 5,665 million, 11.6% up on the third quarter of
 2004. The gross margin ratio (78.7%) was unchanged from the comparable period
 of 2004. Cost of sales continued to fall as a percentage of net sales (25.7%,
 vs. 26.3% in the third quarter of 2004. Other revenues were stable in value
 terms.
     Research and development expenses rose by 1.6% year-on-year to euro 992
 million.
     Selling and general expenses, at euro 2,018 million, were 4.2% higher than
 in the third quarter of 2004, and represented 28.0% of net sales (vs. 30.0% in
 Q3 2004). Promotional expenses grew at a faster rate in the third quarter than
 in the second quarter, while the reduction in general expenses was again more
 marked than in the previous quarter.
     Other current operating income came to euro 59 million, against euro 96
 million in the third quarter of 2004, reflecting a less favorable foreign
 exchange position over the quarter.
     Operating income - current was up 20.2% at euro 2,653 million,
 representing 36.8% of net sales versus 34.2% in the third quarter of 2004, an
 improvement of 2.6 points.
     Other operating income and expenses showed a net gain of euro 37 million,
 compared with a net loss of euro 14 million in the third quarter of 2004. In
 2005, this line includes the euro 70 million gain on the divestment of the
 oral health business to Procter & Gamble.
     Operating income rose by 24.2% to euro 2,687 million.
     Net financial expense came to euro 19 million, compared with euro 213
 million in the third quarter of 2004. This marked improvement reflects firstly
 a lower cost of debt capital, a reduction in debt due to cash flow generated
 by the Group, and a favorable effect from the remeasurement of financial
 instruments; and secondly euro 64 million of gains on the disposal of equity
 holdings (primarily Transkaryotic and Viropharma).
     Income tax expense totaled euro 829 million, compared with euro 583
 million for the third quarter of 2004, giving an effective tax rate of 31.1%
 (vs. 29.9% for the third quarter of 2004).
     The share of profit from associates was euro 175 million, against euro 201
 million for the third quarter of 2004. This line includes the Group's share of
 after-tax profits from the territories managed by BMS under the Plavix(R) and
 Avapro(R) alliance (euro 112 million, vs. euro 107 million for the third
 quarter of 2004). The reduction in the share of profits from associates
 reflects the deconsolidation of Wacker-Chemie GmbH at the start of the third
 quarter.
     Minority interests in net income were euro 91 million, compared with euro
 74 million in the third quarter of 2004. This line includes the share of pre-
 tax profits paid over to BMS from territories managed by sanofi-aventis (euro
 82 million, vs. euro 60 million for the third quarter of 2004).
     Net income was up 28.7% at euro 1,923 million, and represented 26.7% of
 net sales, against 23.2% for the third quarter of 2004.
     Earnings per share (EPS) came to euro 1.44, 27.4% higher than the 2004
 third-quarter figure of euro 1.13, based on an average number of shares of
 1,337,056,282 for the third quarter of 2005 and 1,327,656,093 for the third
 quarter of 2004.
 
     First 9 months of 2005 (vs. adjusted pro forma, first 9 months of 2004)
     In the 9 months to end September 2005, sanofi-aventis generated net sales
 of euro 20,304 million, a rise of 11.0% on a comparable basis. Exchange rate
 movements had a negative effect of 1.2 points, and changes in Group structure
 a negative effect of 0.9 of a point. After allowing for these impacts,
 reported-basis growth was 8.9%.
     Gross profit for the 9 months to end September 2005 was euro 15,899
 million, up 10.4% on the comparable period in 2004. The gross margin ratio was
 78.3%, against 77.2% for the comparable period of 2004. This improvement
 reflects the combined effect of sales growth, productivity gains and
 purchasing efficiencies.
     Research and development expenses were 0.3% higher than in the comparable
 period of 2004 at euro 2,894 million. The lack of significant growth in R&D
 spend reflects the impact of restructuring initiated by Aventis prior to the
 acquisition and the discontinuation of some R&D collaborations.
     Selling and general expenses were 2.0% up on the comparable period of 2004
 at euro 5,967 million, representing 29.4% of net sales. Promotional expenses
 increased faster than sales growth, while general expenses were sharply down.
     Other current operating income came to euro 192 million, against euro 185
 million on the comparable period of 2004, The Group's share of profits from
 alliances, especially the Actonel(R) alliance, continues to grow.
     Operating income - current was up 23.8% at euro 7,052 million,
 representing 34.7% of net sales, an improvement of 4.1 points over the
 comparable period of 2004.
     Other operating income and expenses showed a net gain of euro 44 million,
 compared with euro 180 million for the comparable period of 2004. In 2004,
 this line included gains on divestments of euro 373 million (mainly from
 divestments by Aventis) and bid defense costs of euro 154 million. In 2005, it
 includes the euro 70 million gain on the divestment of the oral health
 business to Procter & Gamble.
     Operating income was up 22.9% at euro 7,063 million, representing 34.8% of
 net sales (vs. 30.8% for the comparable period of 2004).
     Net financial expense came to euro 224 million, versus euro 606 million
 for the comparable period of 2004. This improvement reflects a lower cost of
 debt capital, a reduction in debt due to cash flow generated by the Group, a
 favorable effect from the remeasurement of financial instruments, and gains on
 disposals of equity holdings (primarily Transkaryotic and Viropharma) in 2005.
     Income tax expense was euro 2,131 million, against euro 1,530 million for
 the comparable period of 2004, giving an effective tax rate of 31.2% to end
 September 2005 (vs. 29.8% to end September 2004).
     The share of profit from associates was euro 444 million, compared with
 euro 434 million for the first 9 months of 2004. This line includes the
 Group's share of after-tax profits from the territories managed by BMS under
 the Plavix(R) and Avapro(R) alliance (euro 295 million, vs. euro 265 million
 for the first 9 months of 2004).
     Minority interests amounted to euro 261 million, against euro 215 million
 for the first 9 months of 2004. This line includes the share of pre-tax
 profits paid over to BMS from territories managed by sanofi-aventis (euro 220
 million, vs. euro 175 million for the first 9 months of 2004).
     Net income was up 27.7% at euro 4,891 million, representing 24.1% of net
 sales (vs. 20.5% for the first 9 months of 2004).
     Earnings per share (EPS) came to euro 3.66, 26.6% higher than the figure
 for the first 9 months of 2004 (euro 2.89), based on an average number of
 shares of 1,335,779,796 for the first 9 months of 2005 and 1,326,234,913 for
 the first 9 months of 2004.
 
     Consolidated net debt
     Consolidated net debt (defined as short-term debt plus long-term debt, net
 of cash and cash equivalents) fell from euro 12.8 billion at end June 2005 to
 euro 11.6 billion at end September 2005.
 
     Share issue reserved for employees*
     Under the authority granted by the shareholders' meeting of May 31, 2005,
 the Board of Directors decided at its meeting of November 7, 2005 to carry out
 a share issue reserved for employees before the end of 2005. The main terms of
 the proposed issue are:
     -- maximum issue: 0.5% of the share capital
     -- subscription price: 54.09 euros, i.e. a discount of 20%
     -- lock-up period: 5 years
     -- subscription period: November 21, 2005 through December 2, 2005
 
     In accordance with IFRS, the fair value of the employee benefit arising
 from this share issue will be recognized in the final quarter of 2005.
 
     2005 guidance
     Based on its strong 2005 third-quarter performance, sanofi-aventis
 maintains its 2005 guidance.
     Sanofi-aventis expects 2005 full-year comparable-basis net sales growth to
 be ahead of the world pharmaceutical market growth rate. Barring major adverse
 events, sanofi-aventis also expects 2005 full-year adjusted EPS growth of at
 least 20% (based on an exchange rate of euro 1:$1.25, with sensitivity to the
 euro/dollar exchange rate estimated at 0.5% of growth for a 1-cent movement in
 the exchange rate).
 
     * Read the "Important Information" at the end of this press release
 
     Recent events
     September 6, 2005    Announcement of FDA approval for Ambien CR(TM) in the
                          United States.
     September 6, 2005    Announcement of discontinuation of ACTIVE W arm
                          (clopidogrel + aspirin versus oral anticoagulation)
                          designed to evaluate clopidogrel in the prevention of
                          vascular events in atrial fibrillation patients; the
                          ACTIVE A and ACTIVE I arm of the clinical trial
                          program are to continue.
     September 8, 2005    Recommendation by the FDA advisory committee panel
                          that Exubera(R) be approved for use in adults with
                          type 1 and type 2 diabetes.
     September 13, 2005   Announcement of distribution and supply agreement
                          with Prasco Laboratories to launch an authorized
                          generic version of Allegra(R) in the United States.
     September 13, 2005   Trial date of April 3, 2006 set for the Plavix(R)
                          patent infringement litigation against Apotex Inc.
                          and Apotex Corp. in the United States.
     September 15, 2005   Publication of interim analysis of phase III study on
                          early-stage HER2-positive breast cancer showing
                          Taxotere(R)-based chemotherapy combined with
                          Herceptin(R) improves disease-free survival.
     September 15, 2005   Signature by Sanofi pasteur of a $100 million
                          contract to produce vaccines against the H5N1 bird
                          flu strain for the US government.
     September 21, 2005   Sanofi pasteur announces donation of 200,000 doses of
                          influenza vaccine to support the American
                          government's efforts to tackle health problems in the
                          aftermath of Hurricane Katrina.
     September 26, 2005   Acceptance by the FDA of filing of license
                          application for Pentacel(TM), a new combined
                          pediatric vaccine.
     September 30, 2005   Announcement that Sanofi pasteur and the FDA have
                          been informed of 5 cases of Guillain-Barre syndrome
                          following administration of Menactra. The FDA has
                          requested Sanofi pasteur to inform patients and to
                          report any further cases of Guillain-Barre syndrome.
     October 7, 2005      Announcement that Ambien CR(TM) is available in the
                          United States.
     October 27, 2005     Start of hearings of motion for preliminary
                          injunction in the Allegra(R) patent infringement
                          case.
     October 28, 2005     Announcement by Pfizer and sanofi-aventis that they
                          have been informed by the FDA in the United States
                          that the original review period for the Exubera(R)
                          license application is to be extended by three
                          months.
     November 7, 2005     Decision by the sanofi-aventis Board of Directors to
                          carry out a share issue reserved for Group employees
 
 
     2006 Financial Diary
 
     January 30, 2006     2005 fourth-quarter net sales
     February 24, 2006    2005 results - analyst/investor meeting in Paris
 
 
 
     APPENDICES:
     List of appendices:
     Appendix 1:  Explanatory notes
     Appendix 2:  Net sales by product: third quarter of 2005 and first 9
                  months of 2005
     Appendix 3:  Adjusted consolidated income statements (unaudited): third
                  quarter and first 9 months of 2005
     Appendix 4:  Reconciliation of consolidated income statement to adjusted
                  consolidated income statement (unaudited): third quarter of
                  2005 and first 9 months of 2005
 
     Appendix 1: Explanatory notes
     Comparable net sales: When we refer to the change in our sales on a
 "comparable" basis, we mean that we exclude the impact of exchange rate
 movements and changes in Group structure (acquisitions and divestments of
 interests in entities and rights to products, and changes in consolidation
 method for consolidated entities).
     For any two periods, we exclude the impact of exchange rates by
 recalculating sales for the earlier period on the basis of exchange rates used
 in the later period. We exclude the impact of acquisitions by including sales
 for a portion of the prior period equal to the portion of the current period
 during which we owned the entity or product rights based on sales information
 we receive from the party from whom we make the acquisition.
     Similarly, we exclude sales in the relevant portion of the prior period
 when we have sold an entity or rights to a product.
     For a change in consolidation method, the prior period is recalculated on
 the basis of the method used for the current period.
 
     Reconciliation of 2004 pro forma reported net sales to 2004 pro forma
 comparable net sales
 
     euro million                             2004: 9 months
     Pro forma reported net sales                 18,648
     Impact of changes in Group structure           (161)
     Impact of exchange rates                       (192)
     Pro forma comparable net sales               18,295
 
 
     euro million                                2004: Q3
     Pro forma reported net sales                  6,452
     Impact of changes in Group structure            (38)
     Impact of exchange rates                         74
     Pro forma comparable net sales                6,488
 
     Developed sales: When we refer to "developed sales" of a product, we mean
 consolidated net sales, excluding sales of products to our alliance partners,
 but including those that are made through our alliances and are not included
 in our consolidated net sales (with Bristol-Myers Squibb on Plavix(R)/
 Iscover(R) (clopidogrel) and Aprovel(R)/Avapro(R)/Karvea(R) (irbesartan) and
 with Fujisawa on Stilnox(R)/ Myslee(R)). Our alliance partners provide us with
 information regarding their sales in order to allow us to calculate developed
 sales.
     We believe that developed sales are a useful measurement tool because they
 demonstrate the overall presence of our products in the market.
 
     Reconciliation of net sales to developed sales
 
     euro million                         2005: 9 months    2004: 9 months*
     Net sales                                20,304            18,295
     Non-consolidated sales of Plavix(R)/
      Iscover(R) net of sales of product
      to Bristol-Myers Squibb                  1,900             1,633
     Non-consolidated sales of Aprovel(R)/
      Avapro(R)/Karvea(R) net of sales of
      product to Bristol-Myers Squibb            470               463
     Non-consolidated sales of Stilnox(R)/
      Myslee(R) net of sales of product
      to Fujisawa                                 58                52
     Developed sales                          22,732            20,443
 
     * Pro forma net sales
 
 
     euro million                            2005: Q3           2004: Q3*
     Net sales                                 7,200             6,488
     Non-consolidated sales of Plavix(R)/
      Iscover(R) net of sales of product
      to Bristol-Myers Squibb                    708               660
     Non-consolidated sales of Aprovel(R)/
      Avapro(R)/Karvea(R) net of sales of
      product to Bristol-Myers Squibb            180               179
     Non-consolidated sales of Stilnox(R)/
      Myslee(R) net of sales of product
      to Fujisawa                                 22                19
     Developed sales                           8,110             7,346
 
     * Pro forma net sales
 
 
     Adjusted net income: We define "adjusted net income" as accounting net
 income (determined under IFRS) adjusted to exclude (i) the material impacts of
 purchase accounting for the Aventis acquisition and (ii) acquisition-related
 integration and restructuring costs. Sanofi-aventis believes that eliminating
 these impacts from net income gives investors a better understanding of the
 underlying economic performance of the combined Group.
     The material impacts of the application of purchase accounting to the
 acquisition are as follows:
     -- charges arising from the remeasurement of Aventis inventories at fair
        value, net of tax;
     -- amortization/impairment expense generated by the remeasurement of
        Aventis intangible assets, net of tax;
     -- any impairment charged against the goodwill arising on the acquisition.
 
     Sanofi-aventis also excludes acquisition-related integration and
 restructuring costs from adjusted net income.
 
     The adjusted pro forma income statements for the third quarter of 2004 and
 the first 9 months of 2004 are presented for comparability purposes as though
 the offer for Aventis, and the transactions described below, had occurred on
 January 1, 2004. The basis of preparation of the pro forma income statements
 is as follows:
     -- Elimination of the income statement contribution of Arixtra,
        Fraxiparine and Campto.
     -- Elimination of Aventis Behring, divested at the start of 2004.
 
 
     euro million    2005: 9 months  2005: 9 months  2004: 9 months
                     consolidated      adjusted        adjusted
                      (unaudited)    consolidated     pro forma
                                      (unaudited)    (unaudited)
     Net sales          20,304            20,304        18,648
     Net income          1,802             4,891         3,830
     Basic EPS (in euros) 1.35              3.66          2.89
 
     euro million     2005: Q3         2005: Q3        2004: Q3
                    consolidated       adjusted        adjusted
                     (unaudited)     consolidated      pro forma
                                      (unaudited)     (unaudited)
     Net sales           7,200             7,200         6,452
     Net income            715             1,923         1,494
     Basic EPS (in euros) 0.54              1.44          1.13
 
 
     Appendix 2: Net sales by product
 
     Third quarter of 2005: Net sales by product
 
     euro  million        Q3 2005     Q3 2004     Q3 2004
                         net sales   pro forma   pro forma
                                     net sales   net sales
                                    (comparable)
     Lovenox(R)              551        484        480
     Plavix(R)               534        435        428
     Allegra(R)              367        370        367
     Taxotere(R)             420        369        366
     Stilnox(R)/Ambien(R)    419        397        397
     Eloxatin(R)             422        329        327
     Lantus(R)               325        225        224
     Tritace(R)              260        243        237
     Aprovel(R)              225        196        193
     Copaxone(R)             240        194        192
     Amaryl(R)               195        163        162
     Actonel(R)               99         82         80
     Depakine(R)              81         77         76
     Xatral(R)                80         69         68
     Nasacort(R)              65         70         69
     Total                 4,283      3,703      3,666
     Other products        2,200      2,224      2,231
     Total Pharmaceuticals 6,483      5,927      5,897
     Vaccines                717        561        555
     Total net sales       7,200      6,488      6,452
 
 
     First 9 months of 2005: Net sales by product
 
     euro million                2005: 9-month     2004: 9-month  2004: 9-month
                                    net sales         pro forma     pro forma
                                                      net sales     net sales
                                                    (comparable)
     Lovenox(R)                        1,571           1,358         1,385
     Plavix(R)                         1,508           1,242         1,232
     Allegra(R)                        1,185           1,094         1,130
     Taxotere(R)                       1,184           1,058         1,077
     Stilnox(R)/Ambien(R)              1,089           1,012         1,041
     Eloxatin(R)                       1,141             844           861
     Lantus(R)                           869             585           599
     Tritace(R)                          724             711           707
     Aprovel(R)                          661             579           577
     Copaxone(R)                         646             522           534
     Amaryl(R)                           542             483           492
     Actonel(R)                          275             219           220
     Depakine(R)                         238             226           225
     Xatral(R)                           237             204           204
     Nasacort(R)                         206             208           214
     Total                            12,076          10,345        10,498
     Other products                    6,809           6,753         6,935
     Total Pharmaceuticals            18,885          17,098        17,433
     Vaccines                          1,419           1,197         1,215
     Total net sales                  20,304          18,295        18,648
 
 
     Appendix 3: Adjusted consolidated income statements (unaudited) for the
 third quarter and first 9 months of 2005
 
     The adjusted consolidated income statements are derived from the
 consolidated income statements as presented in Appendix 4.
 
     Sanofi-aventis 2005 third-quarter adjusted consolidated income statement
 
     euro million       Q3 2005    as %       Q3 2004       as %     % change
                        Adjusted   of        Adjusted       of net
                    consolidated   net      pro forma       sales
                         income    sales       income
                       statement            statement
                      (unaudited)          (unaudited)
 
     Net sales             7,200    100%        6,452        100%      +11.6%
      Other revenues         318    4.4%          324        5.0%       -1.9%
      Cost of sales       (1,853) (25.7%)      (1,700)     (26.3%)       9.0%
     Gross profit          5,665   78.7%        5,076       78.7%      +11.6%
      Research &
       development
       expenses             (992) (13.8%)        (976)     (15.1%)      +1.6%
      Selling & general
       expenses           (2,018) (28.0%)      (1,937)     (30.0%)      +4.2%
      Other current
       operating income       59     --            96         --       -38.5%
      Other current
       operating
       expenses              (30)    --           (21)        --       +42.9%
      Amortization of
       intangibles           (31)    --           (30)        --          --
     Operating income
      - current            2,653   36.8%        2,208       34.2%      +20.2%
      Restructuring
       costs                  (3)    --           (31)        --          --
      Impairment of PP&E
       and intangibles         0     --             0         --          --
      Other operating
       income and
       expenses               37     --           (14)        --          --
     Operating income      2,687   37.3%        2,163       33.5%      +24.2%
      Financial
       expenses             (123)    --          (199)        --       -38.2%
      Financial income       104     --           (14)        --          --
     Income before tax
      and associates       2,668   37.1%        1,950       30.2%      +36.8%
      Income tax
       expense              (829) (11.5%)        (583)      (9.0%)     +42.2%
      Effective tax
       rate                 31.1%    --          29.9%         --         --
      Share of profit/
       loss of
       associates            175     --           201          --      -12.9%
     Net income before
      minority
      interests            2,014   28.0%        1,568       24.3%      +28.4%
      Minority
       interests             (91)    --           (74)         --      +23.0%
     Net income            1,923   26.7%        1,494        23.2%     +28.7%
      Average number
       of shares
       outstanding 1,337,056,282        1,327,656,093                     --
     Earnings per
      share
      (in euros)            1.44                 1.13                  +27.4%
 
 
 
     Sanofi-aventis consolidated income statement: first 9 months of 2005
 
     euro million  2005: 9 months  as %  2004: 9 months     as %      % change
                        Adjusted   of       Adjusted        of net
                    consolidated   net      pro forma       sales
                          income  sales      income
                       statement            statement
                      (unaudited)          (unaudited)
 
     Net sales            20,304    100%       18,648         100%      +8.9%
      Other revenues         866    4.3%          831         4.5%      +4.2%
      Cost of sales       (5,271) (26.0%)      (5,079)      (27.3%)     +3.8%
     Gross profit         15,899   78.3%       14,400        77.2%     +10.4%
      Research &
       development
       expenses           (2,894) (14.3%)      (2,885)      (15.5%)     +0.3%
      Selling & general
       expenses           (5,967) (29.4%)      (5,848)      (31.4%)     +2.0%
      Other current
       operating income      192     --           185          --       +3.8%
      Other current
       operating expenses    (94)    --           (69)         --      +36.2%
      Amortization of
       intangibles           (84)    --           (86)         --       -2.3%
     Operating income
      - current            7,052   34.7%        5,697        30.6%     +23.8%
      Restructuring costs    (30)    --          (130)         --      -76.9%
      Impairment of PP&E
       and intangibles        (3)    --            --          --        --
      Other operating income
       and expenses           44     --           180          --        --
     Operating income      7,063   34.8%        5,747        30.8%     +22.9%
      Financial expenses    (428)    --          (691)         --      -38.1%
      Financial income       204     --            85          --        --
     Income before tax
      and associates       6,839   33.7%        5,141        27.6%     +33.0%
      Income tax expense  (2,131) (10.5%)      (1,530)       (8.2%)    +39.3%
      Effective tax rate    31.2%    --          29.8%         --        --
      Share of profit/loss
       of associates         444     --           434          --       +2.3%
     Net income before
      minority interests   5,152   25.4%        4,045        21.7%     +27.4%
      Minority interests    (261)    --          (215)         --      +21.4%
     Net income            4,891   24.1%        3,830        20.5%     +27.7%
      Average number of
       shares
       outstanding 1,335,779,796        1,326,234,913                    --
     Earnings per
      share
      (in euros)            3.66                 2.89                  +26.6%
 
 
     Appendix 4: Reconciliation of consolidated income statement to adjusted
 consolidated income statement (unaudited) for the third quarter of 2005 and
 the first 9 months of 2005
 
     Third quarter of 2005:
      The adjustments to the income statement reflect the elimination of
      material impacts of the application of purchase accounting to the Aventis
      acquisition (euro 1,140 million net of deferred taxes, with no cash
      impact for the Group) and restructuring charges (euro 68 million net of
      tax), i.e. a total impact of euro 1,208 million.
 
     Third quarter of 2005: Reconciliation of consolidated income statement to
     adjusted consolidated income statement (unaudited)
 
     euro million                   Q3 2005         Adjustments     Q3 2005
                                 consolidated                      adjusted
                                  (unaudited)                  consolidated
                                                                (unaudited)
     Net sales                         7,200              --         7,200
      Other revenues                     318              --           318
      Cost of sales                   (1,972)            119(a)     (1,853)
     Gross profit                      5,546             119         5,665
      Research & development expenses   (992)             --          (992)
      Selling & general expenses      (2,018)             --        (2,018)
      Other current operating income      59              --            59
      Other current operating expenses   (30)             --           (30)
      Amortization of intangibles       (974)            943(b)        (31)
     Operating income - current        1,591           1,062         2,653
      Restructuring costs               (111)            108(c)         (3)
      Impairment of PP&E
       and intangibles                  (651)            651(d)          0
      Other operating income
       and expenses                       37              --            37
     Operating income                    866           1,821         2,687
      Financial expenses                (123)             --          (123)
      Financial income                   104              --           104
     Income before tax and associates    847           1,821         2,668
      Income tax expense                (141)           (688)(e)      (829)
      Share of profit/loss of associates  99              76(f)        175
     Net income before minority
      interests                          805           1,209         2,014
      Minority interests                 (90)             (1)(g)       (91)
     Net income                          715           1,208         1,923
      Average number of shares
       outstanding             1,337,056,282                 1,337,056,282
     Earnings per share (in euros)      0.54                          1.44
 
     The material impacts of the application of purchase accounting to the
 Aventis acquisition and of restructuring charges on the 2005 third-quarter
 consolidated income statement are as follows:
     (a)  A charge of euro 119 million arising from the workdown of acquired
          inventories remeasured at fair value. This adjustment has no cash
          impact on the Group.
     (b)  An amortization charge of euro 943 million against intangible assets.
          This adjustment has no cash impact on the Group.
     (c)  A pre-tax restructuring charge of euro 108 million.
     (d)  Impairment losses of euro 651 million, mainly relating to Allegra.
          This adjustment has no cash impact on the Group.
     (e)  The tax impact primarily comprises:
          (1) Deferred taxes of euro 648 million generated by the amortization
              charge of euro 943 million taken against intangible assets; by
              impairment of intangibles of euro 651 million; and by a euro 119
              million charge arising from the workdown of inventories
              remeasured at fair value. This adjustment has no cash impact on
              the Group.
          (2) A tax saving of euro 40 million on the euro 108 million of
              restructuring charges.
     (f) The impact on "Share of profit/loss from associates" comprises:
          (1) A charge of euro 21 million corresponding to the amortization of
              intangibles (net of tax) and the workdown of acquired
              inventories. This adjustment has no cash impact on the Group.
          (2) A post-tax impairment loss of euro 55 million relating to
              Hexavac. This adjustment has no cash impact on the Group.
     (g) In "Minority interests", an impact of euro 1 million representing the
         share attributable to minority shareholders of amortization charged
         against intangibles. This adjustment has no cash impact on the Group.
 
 
     First 9 months of 2005:
 
     The adjustments to the income statement reflect the elimination of
 material impacts of the application of purchase accounting to the Aventis
 acquisition (euro 2,624 million net of deferred taxes, with no cash impact for
 the Group) and restructuring charges (euro 465 million net of tax), i.e. a
 total impact of euro 3,089 million.
 
     First 9 months of 2005: Reconciliation of consolidated income statement to
 adjusted consolidated income statement (unaudited)
 
     euro million                2005: 9 months   Adjustments   2005: 9 months
                                  consolidated                    adjusted
                                   (unaudited)                  consolidated
                                                                 (unaudited)
     Net sales                        20,304              --        20,304
      Other revenues                     866              --           866
      Cost of sales                   (5,662)            391(a)     (5,271)
     Gross profit                     15,508             391        15,899
      Research & development expenses (2,894)             --        (2,894)
      Selling & general expenses      (5,967)             --        (5,967)
      Other current operating income     192              --           192
      Other current operating expenses   (94)             --           (94)
      Amortization of intangibles     (2,944)          2,860(b)        (84)
     Operating income - current        3,801           3,251         7,052
      Restructuring costs               (749)            719(c)        (30)
      Impairment of PP&E and
       intangibles                      (757)            754(d)         (3)
      Other operating income
       and expenses                       44              --            44
     Operating income                  2,339           4,724         7,063
      Financial expenses                (428)             --          (428)
      Financial income                   204              --           204
     Income before tax and associates  2,115           4,724         6,839
      Income tax expense                (373)         (1,758)(e)    (2,131)
      Share of profit/loss of associates 307             137(f)        444
     Net income before
      minority interests               2,049           3,103         5,152
      Minority interests                (247)            (14)(g)      (261)
     Net income                        1,802           3,089         4,891
      Average number of shares
       outstanding             1,335,779,796                 1,335,779,796
     Earnings per share (in euros)      1.35                          3.66
 
     The material impacts of the application of purchase accounting to the
 Aventis acquisition and of restructuring charges on the consolidated income
 statement for the first 9 months of 2005 are as follows:
     (a) A charge of euro 391 million arising from the workdown of acquired
         inventories remeasured at fair value. This adjustment has no cash
         impact on the Group.
     (b) An amortization charge of euro 2,860 million against intangible
         assets. This adjustment has no cash impact on the Group.
     (c) A pre-tax restructuring charge of euro 719 million.
     (d) Impairment losses of euro 754 million, mainly relating to Allegra.
         This adjustment has no cash impact on the Group.
     (e) The tax impact primarily comprises:
          (1) Deferred taxes of euro 1,504 million generated by the
              amortization charge of euro 2,860 million taken against
              intangible assets; by impairment of intangibles of euro 754
              million; and by a euro 391 million charge arising from the
              workdown of inventories remeasured at fair value. This adjustment
              has no cash impact on the Group.
          (2) A tax saving of euro 254 million on the euro 719 million of
              restructuring charges.
     (f) The impact on "Share of profit/loss from associates" comprises:
          (1) A charge of euro 82 million corresponding to the amortization of
              intangibles (net of tax) and the workdown of acquired
              inventories. This adjustment has no cash impact on the Group.
          (2) A post-tax impairment loss of euro 55 million, relating primarily
              to Hexavac. This adjustment has no cash impact on the Group.
     (g) In "Minority interests", an impact of euro 14 million representing the
              share attributable to minority shareholders of charges for the
              amortization and impairment of intangibles. This adjustment has
              no cash impact on the Group.
 
 
     REMINDER
     The 3rd quarter 2005 results will be reviewed at 8.00 am (Paris time) by
 Mr. Hanspeter Spek, Executive Vice-President Pharmaceutical Operations and Mr.
 Jean-Claude Leroy, Senior Vice-President CFO. The slides will be available on
 http://www.sanofi-aventis.com. This presentation will be followed by a Q&A
 session.
 
     CALL-IN NUMBERS    The conference will also be available on telephone via
                        the following numbers:
 
                        France +33 (0) 1 71 23 04 18
                        UK     +44 (0) 207 365 1849
                        USA    +1 718 354 1172
 
 
     AUDIO REPLAY       Available online at http://www.sanofi-aventis.com and
                        through the numbers below (until November 18, 2005):
 
                        France       +33 (0) 1 71 23 02 48
                        UK           +44 (0) 207 784 1024
                        USA          +1 718 354 1112
                        Access code  7979744#
 
     Important Information
     This press release does not constitute an offer to sell or a solicitation
 of offers to purchase sanofi-aventis shares. The employee share offering will
 only be carried out in those jurisdictions in which such offering may be made
 pursuant to a prospectus or registration statement that has been filed with
 and/or approved by the relevant local authorities, or pursuant to an exemption
 from the requirement to file or publish a prospectus or registration
 statement.  More generally, the offering will only be made in jurisdictions in
 which all required local filings and notices have been made and approvals
 obtained. This press release is not intended for any jurisdiction in which
 such a prospectus has not been approved or such an exemption is not available,
 or in which all other required filings and notifications have not been made or
 approvals obtained.
 
     (1) Refer to the Appendices for definitions of financial indicators
     (2) Based on an exchange rate of euro 1:$1.25. Sensitivity to the
         euro/dollar exchange rate is estimated at 0.5% of growth for a 1-cent
         movement in the exchange rate.
     (3) IMS NPA 3 channels -YTD September 2005
     (4) IMS NPA 3 channels -September 2005
     (5) Source: Intrinsiq Research - rolling 3 months to August 2005
         (excluding Herceptin(R) only patients in early stage breast cancer)
 
     About sanofi-aventis
     The sanofi-aventis Group is the world's third largest pharmaceutical
 company, ranking number one in Europe. Backed by a world-class R&D
 organization, sanofi-aventis is developing leading positions in seven major
 therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases,
 central nervous system, internal medicine, and vaccines. The sanofi-aventis
 Group is listed in Paris (EURONEXT: SAN) and in New York (NYSE:   SNY)
 
     Forward-Looking Statements
     This press release contains forward-looking statements as defined in the
 Private Securities Litigation Reform Act of 1995. Forward-looking statements
 are statements that are not historical facts. These statements include
 financial projections and estimates and their underlying assumptions,
 statements regarding plans, objectives and expectations with respect to future
 operations, products and services, and statements regarding future
 performance. Forward-looking statements are generally identified by the words
 "expect," "anticipates," "believes," "intends," "estimates," "plans" and
 similar expressions. Although sanofi-aventis' management believes that the
 expectations reflected in such forward-looking statements are reasonable,
 investors are cautioned that forward-looking information and statements are
 subject to various risks and uncertainties, many of which are difficult to
 predict and generally beyond the control of sanofi-aventis, that could cause
 actual results and developments to differ materially from those expressed in,
 or implied or projected by, the forward-looking information and statements.
 These risks and uncertainties include those discussed or identified in the
 public filings with the SEC and the AMF made by sanofi-aventis, including
 those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-
 Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year
 ended December 31, 2004. Other than as required by applicable law, sanofi-
 aventis does not undertake any obligation to update or revise any forward-
 looking information or statements. The sanofi-aventis Group conducts its
 business in the United States through its subsidiaries Sanofi-Synthelabo Inc.,
 Aventis Pharmaceuticals Inc. and Sanofi Pasteur Inc.
 
     Contact: Jean-Marc Podvin, 33 1.53.77.42.23,
              jean-marc.podvin@sanofi-aventis.com
 
 

SOURCE sanofi-aventis

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.